Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deleobuvir + Faldaprevir + Ribavirin in HCV with Hepatic Impairment
NCT01830127Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of deleobuvir in hepatitis C virus infection, sponsored by Boehringer Ingelheim. Started Apr 2013; status: completed.
02
Drugs
deleobuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT01830127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830127.